Biden's State of the Union pitch on expanding Medicare drug price negotiation

Biden wants to more than double the size of Medicare's new drug price negotiation program, he'll say in his State of the Union address.

March 6, 2024 Check out STAT+

Sponsored By

Andrew Harnik/AP Biden to propose expanding Medicare drug price negotiation in State of the Union Biden wants to more than double the size of Medicare's new drug price negotiation program, he'll say in the State of the Union Thursday. By Rachel Cohrs Florida health officials provide scant details on measles cases, worrying health experts The information vacuum leaves in the dark anyone in the public who might be concerned about whether they may have had an exposure. By Helen Branswell STAT+ | With Meta's backing, Headspace launches into VR Headspace XR, developed with funding from Meta, guides users through meditation and other activities, such as a Tai Chi-inspired game. By Mario Aguilar Spencer Platt/Getty Images Opinion: The CDC's new, relaxed Covid isolation guidance makes perfect sense The CDC's new guidance recognizes something important: What made sense in 2020 for Covid does not work for most people in 2024. By Ashish K. Jha STAT+ | Oracle Health chair says Cerner isn't competing with Epic Cerner's new owner aims to win customers with cloud services instead of just electronic health records, Oracle Health's chair tells STAT.  By Mohana Ravindranath STAT+ | Senate panel advances bill to ban some Chinese biotechs, with Sen. Paul taking up industry's cause A Senate panel passed a bill aimed at preventing some Chinese biotechs from doing business in the U.S. Sen. Rand Paul says it goes too far. By John Wilkerson FREDERIC J. BROWN/AFP via Getty Images Air quality improvements belie rising racial and ethnic disparities in pollutant-related deaths, study finds New report finds progress in public health consequences of nitrogen dioxide and particulate pollution, but ethnic, racial health disparities increased. By Annalisa Merelli STAT+ | Startup Alumis raises $259 million as it prepares for psoriasis trial The company's oral medicine is designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser